When life gives you lemons, make lemonade. Glaxo Wellcome PLC seems to be taking this homily to heart. The firm was naturally disappointed that it had to withdraw troglitazone (Romozin), a new treatment for Type II diabetes, from the UK market in December 1997, just four months after launch. Although the action was voluntary, Glaxo felt it had little choice. By then, the drug's originator Sankyo Co. Ltd. , and its North American licensee Parke-Davis , a division of Warner-Lambert Co. , (which sold it as Rezulin), had catalogued too many adverse effects on patients' livers to allow it to get through European approvals.
The problems with troglitazone only really started showing up once the drug came to market, and started being used in patient populations far larger than those assembled for clinical trials....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?